Posted On: 10/29/2015 7:22:52 PM
Post# of 30066
Jason Napodano valued Eltoprazine at $70 million in April of this year.
I'll take half.
I'll take half.
Quote:
"For eltoprazine, we have built a detailed financial model forecasting sales in both PD-LID and ADHD, with a 22% discount rate (comparable to the recent Series-E financings) and various probabilities of success (25% for LID, 10% for ADHD). Our NPV model pegs eltoprazine to be worth $70 million."
(0)
(0)
